| Literature DB >> 29867733 |
Soila Järvenpää1, Eija Rosti-Otajärvi1, Sirpa Rainesalo1, Linda Laukkanen1, Kai Lehtimäki1, Jukka Peltola1,2.
Abstract
BACKGROUND: Deep brain stimulation (DBS) of the anterior nucleus of thalamus (ANT) is an emerging treatment option for patients suffering from refractory epilepsy. ANT has extensive connections with hippocampus and retrosplenial cingulum, areas associated mainly with spatial memory and with anterior cingulum which is important in executive functions. As refractory epilepsy is often associated with cognitive decline and neuronal damage, the decreased connectivity between ANT and remote structures might impact on the effects of DBS.Entities:
Keywords: anterior nucleus of thalamus; connectivity; deep brain stimulation; executive functions; neuropsychological evaluation; patient selection; refractory epilepsy; seizure
Year: 2018 PMID: 29867733 PMCID: PMC5952045 DOI: 10.3389/fneur.2018.00324
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Main connections of anterodorsal (AD), AV, and AM subnuclei of anterior nucleus of thalamus. AM connects to frontal areas medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC) (in blue). AV is connected to subicular cortex of hippocampus both directly and indirectly via the retrosplenial cortex (in yellow). The medial mammillary nucleus receives axons from AV and the lateral mammillary nucleus from AD (in orange).
Figure 2Schematic illustration of visible landmarks in 3T MRI sagittal plane and ANT normalized coordinate system, where the anterior border of ANT is set to 1 and its posterior border to 0 on the y-axis. In all, 74% of the deep brain stimulation contacts situated in the anterior side of the cutoff level 0.58 (blue color) lead to a favorable outcome to the treatment. By contrast, 83% of the contacts situated posterior to this cutoff level (red color) were nonresponders. Abbreviations: AM, anteromedial nucleus of ANT; AV, anteroventral nucleus of ANT; Th, thalamus; Ve. I, lateral ventricle; mmt, mammillothalamic tract; ANT, anterior nucleus of thalamus (11).
Patient demographics as described by age, sex, years of education, etiology of epilepsy, MRI findings, localization of epileptic zone by scalp EEG, antiepileptic drugs (AED), and outcome status defined by at least a 50% reduction in seizure frequency.
| Patient | Age | Education (years) | Etiology | MRI | Epileptic zone | AED | Responder |
|---|---|---|---|---|---|---|---|
| 1 | 31–35 | 12 | Encephalitis | Normal | Multifocal | CBZ, LCM | Yes |
| 2 | 26–30 | 9 | Encephalitis | Normal | Multifocal | CLB, OXC, ZNS | Yes |
| 3 | 26–30 | 12 | CD | Bilateral perisylvian polymicrogyria | Multifocal | OXC | Yes |
| 4 | 51–55 | 12 | Encephalitis | Right parietal and temporal inflammatory lesion | Right temporal | CLB, OXC, ZNS | Yes |
| 5 | 26–30 | 12 | Encephalitis | Bilateral parietal inflammatory lesion | Multifocal | CLN, PHT | Yes |
| 6 | 51–55 | 12 | Unknown | Normal | Unknown | LCM, LEV, VPA | Yes |
| 7 | 36–40 | 12 | CD | Hemimegalencephalia | Right frontal | CLB, OXC, ZNS | Yes |
| 8 | 31–35 | 9 | CD | Bilateral periventricular heterotopia | Multifocal | CBZ, CLB | Yes |
| 9 | 36–40 | 9 | CD | Left frontal cortical dysplasia | Left frontal | CLB, LTG, VPA, ZNS | Yes |
| 10 | 31–35 | 16 | CD | Bilateral periventricular heterotopia | Multifocal | CBZ, LCM, LEV, ZNS | Yes |
| 11 | 56–60 | 9 | Unknown | Normal | Multifocal | CLB, LCM, LEV, OXC | Yes |
| 12 | 26–30 | 12 | Unknown | Normal | Right frontal | CLB, LCM, OXC | Yes |
| 13 | 51–55 | 12 | CD | Bilateral perisylvian polymicrogyria | Right temporal | CBZ, CLB, ZNS | No (dead) |
| 14 | 21–25 | 12 | Unknown | Normal | Left parietal | CBZ, CLB | No (dead) |
| 15 | 26–30 | 9 | Encephalitis | Normal | Multifocal | CLB, OXC, TPR | No |
| 16 | 46–50 | 12 | Unknown | Normal | Right frontal | OXC, VPA, ZNS | No |
CD, cortical dysplasia; CBZ, carbamazepine; CLB, clobazam; CLN, clonazepam; LCM, lacosamide; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PHT, phenytoin; TPR, topiramate; VPA, valproate; ZNS, zonisamide.
Figure 3Composite Z-scores in different cognitive domains in responders (n = 12, in blue) and nonresponders (n = 4, in red).
Severity of cognitive dysfunction based on Z values in responders and nonresponders.
| Responders ( | Normal ( | Mild (−2 < | Moderate (−3 < | Severe ( |
|---|---|---|---|---|
| WAIS-III | ||||
| Digit span | 3 (25.0%) | 5 (41.7%) | 4 (33.3%) | 0 (0%) |
| COWAT | ||||
| Animal fluency | 1 (8.3%) | 5 (41.7%) | 2 (16.7%) | 4 (33.3%) |
| Word fluency | 3 (25.0%) | 4 (33.3%) | 2 (16.7%) | 3 (25.0%) |
| Trail-Making Test (TMT) | ||||
| Part A (s) | 5 (41.7%) | 1 (8.3%) | 1 (8.3%) | 5 (41.7%) |
| Part B (s) | 1 (8.3%) | 2 (16.7%) | 1 (8.3%) | 8 (66.7%) |
| Stroop | ||||
| Color-word | 0 (0%) | 4 (44.4%) | 3 (33.3%) | 2 (22.2%) |
| ROCFT | ||||
| Immediate recall | 2 (16.7%) | 4 (33.3%) | 4 (33.3%) | 2 (16.7%) |
| RAVLT | ||||
| Total recall | 3 (27.3%) | 5 (45.5%) | 2 (18.2%) | 1 (9.1%) |
| Post-interference recall | 5 (45.5%) | 0 (0%) | 5 (45.5%) | 1 (9.1%) |
| Recognition | 6 (75.0%) | 1 (12.5%) | 1 (12.5%) | 0 (0%) |
| WAIS-III | ||||
| Similarities | 6 (54.5%) | 4 (36.4%) | 1 (9.1%) | 0 (0%) |
| ROCFT | ||||
| Copy | 6 (50.0%) | 2 (16.7%) | 4 (33.3%) | 0 (0%) |
| WAIS-III | ||||
| Block design | 6 (54.5%) | 3 (27.3%) | 2 (18.2%) | 0 (0%) |
| WAIS-III | ||||
| Digit span | 0 (0%) | 2 (50.0%) | 2 (50.0%) | 0 (0%) |
| COWAT | ||||
| Animal fluency | 0 (0%) | 0 (0%) | 1 (50.0%) | 1 (50.0%) |
| Word fluency | 0 (0%) | 1 (50.0%) | 0 (0%) | 1 (50.0%) |
| TMT | ||||
| Part A (s) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (100%) |
| Part B (s) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (100%) |
| Stroop | ||||
| Color-word | 0 (0%) | 1 (50.0%) | 0 (0%) | 1 (50.0%) |
| ROCFT | ||||
| Immediate recall | 0 (0%) | 2 (100%) | 0 (0%) | 0 (0%) |
| RAVLT | ||||
| Total recall | 1 (33.3%) | 2 (66.7%) | 0 (0%) | 0 (0%) |
| Post-interference recall | 1 (50.0%) | 1 (50.0%) | 0 (0%) | 0 (0%) |
| Recognition | 2 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WAIS-III | ||||
| Similarities | 1 (25.0%) | 2 (50.0%) | 1 (25.0%) | 0 (0%) |
| ROCFT | ||||
| Copy | 1 (33.3%) | 1 (33.3%) | 0 (0%) | 1 (33.3%) |
| WAIS-III | ||||
| Block design | 1 (25.0%) | 1 (25.0%) | 2 (50.0%) | 0 (0%) |
Values shown are number of patients (percentages in parentheses).
WAIS-III, Wechsler Adult Intelligence Scale III; COWAT, Controlled Oral Word Association Test; RAVLT, Rey Auditory Verbal Learning Test; ROCFT, Rey-Osterrieth Complex Figure Test.
.
.
.
.
Raw scores (mean, SD) and Z-scores (mean, SD) of responders (n = 12) and nonresponders (n = 4).
| Raw score for responders (SD) | Raw score for nonresponders (SD) | |||
|---|---|---|---|---|
| Wechsler Adult Intelligence Scale III (WAIS-III) | ||||
| Digit span | 9.9 (3.3) | 6.3 (2.1) | −1.3 (0.9) | −2.1 (0.5) |
| Controlled Oral Word Association Test | ||||
| Animal fluency | 12.4 (5.3) | 7.5 (2.1) | −2.3 (1.1) | −3.0 (0.6) |
| Word fluency | 23.7 (12.2) | 14.0 (15.6) | −1.8 (1.1) | −2.7 (1.5) |
| Trail-Making Test | ||||
| Part A (s) | 46.0 (18.9) | 138.3 (113.8) | −2.3 (2.4) | −12.1 (12.2) |
| Part B (s) | 153.7 (60.7) | 385.0 (311.9) | −4.2 (3.1) | −14.3 (13.9) |
| Stroop | ||||
| Color-word | 27.3 (8.9) | 21.5 (12.0) | −2.4 (1.1) | −2.4 (1.7) |
| Rey-Osterrieth Complex Figure Test (ROCFT) | ||||
| Immediate recall | 13.1 (6.1) | 13.0 (5.7) | −1.8 (1.1) | −1.8 (0.2) |
| Rey Auditory Verbal Learning Test | ||||
| Total recall | 40.5 (9.2) | 44.3 (0.6) | −1.6 (1.0) | −1.1 (0.1) |
| Post-interference recall | 6.4 (3.4) | 9.0 (1.4) | −1.6 (1.2) | −0.8 (0.6) |
| Recognition | 13.3 (2.0) | 14.0 (1.4) | −0.3 (1.1) | 0.1 (1.2) |
| WAIS-III | ||||
| Similarities | 18.6 (5.1) | 10.8 (4.9) | −0.7 (0.9) | −1.5 (0.7) |
| ROCFT | ||||
| Copying time (s) | 325.1 (140.4) | 540.3 (106.0) | ||
| Copy | 32.8 (2.0) | 24.7 (15.3) | −1.2 (1.3) | −4.6 (6.3) |
| WAIS-III | ||||
| Block design | 32.9 (10.4) | 19.5 (9.3) | −0.8 (0.7) | −1.6 (0.6) |
Figure 4Composite Z-scores in different cognitive domains for patients in whom both preoperative and postoperative neuropsychological evaluations were available (n = 5).